Global hiring within the ZRG Life Sciences Index was up 11.1% from the first quarter, finishing at 87.8, the second highest level over the last 9 quarters. Demand for new employees in Europe drove the index up globally as EMA reported a 34% increase in hiring levels overall. Medical device and diagnostics accounted for much of the growth, with over 1,300 new jobs sited in our index companies alone.
What’s Hot
- Europe is hiring! The EMA numbers are showing a new all-time high mark for total demand;
- Medical Device and Diagnostics is rebounding with a 22.8% increase in job opportunities around the world;
- Hiring for sales talent has returned with a 40% increase in sales talent opportunities within the index companies;
- Manufacturing roles jumped 100% in the quarter reflecting the trend of geographic shifts in where product is made around the world.
What’s Not
- Demand in Asia Pacific dropped by 11% in the quarter, perhaps reflecting a slowing growth rate;
- Quality, Regulatory and Clinical jobs dropped 16% from last quarter, although the total number of roles still remains robust;
- Research and Development Roles dipped 11%.
- Private Equity Investment in the sector is still off 50% from last year’s levels.
While EMA was the regional story, with a broad increase in hiring across medical device and pharma, one juggernaut is leading the charge. Novartis had a large increase in “job share” in this quarter’s index, with increased activities across all functions and regions in EMA. Driving hiring in the medical device and diagnostics in EMA was the big three led by Siemens, Philips and GE Medical. The America’s showed growth of 8% in new and open jobs in the quarter while APAC retreated 11.5%.
For a full copy of the report, go to www.zrgpartners.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.